International Journal of Hematology

, Volume 91, Issue 1, pp 124–127

Influenza A/pandemic 2009/H1N1 in the setting of allogeneic hematopoietic cell transplantation: a potentially catastrophic problem in a vulnerable population

  • Mohamed A. Kharfan-Dabaja
  • Ana Velez
  • Karla Richards
  • John N. Greene
  • Teresa Field
  • Ramon Sandin
Case Report

Abstract

We describe Influenza A/pandemic 2009/H1N1 in two allogeneic hematopoietic cell transplantation recipients. The main presentation in both cases consisted of flu-like symptoms manifesting as, fever, arthralgias and myalgias. The virus was isolated in one case from a throat swab and in another case following a bronchoalveolar lavage. Both patients received oseltamivir at a dose of 75 mg orally twice day. The dose of oseltamivir was increased to 150 mg twice per day due to the lack of improvement or progression of symptoms. In one case, clinical symptoms resolved without sequelae. In the second case, pulmonary symptomatology continued to deteriorate, despite aggressive polymicrobial treatment, requiring mechanical ventilation and ultimately the patient died from respiratory failure. These cases highlight the potentially serious effect of the ongoing Influenza A/pandemic 2009/H1N1 pandemic in this very vulnerable population and the urgent need to establish emergency preparedness strategies by oncology and bone marrow transplantation staff to face this serious healthcare challenge.

Keywords

Influenza A/pandemic 2009/H1N1 Allogeneic hematopoietic cell transplantation 

References

  1. 1.
    Update: novel Influenza A (H1N1) virus infection—Mexico, March–May 2009. MMWR Morb Mortal Wkly Rep 2009;58:467–470.Google Scholar
  2. 2.
    World Health Organization. World now at the start of 2009 influenza pandemic. Statement to the press by WHO Director-General Dr Margaret Chan, 11 June 2009. http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/print.html). Accessed 17 Sept 2009.
  3. 3.
    United States Centers for Disease Control and Prevention. Novel H1N1 flu situation update: 4 Sept 2009. http://www.cdc.gov/h1n1flu/update.htm).
  4. 4.
    Vaillant L, La Ruche G, Tarantola A, Barboza P. Epidemic intelligence team at InVS. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro Surveill. 2009;14:19309.Google Scholar
  5. 5.
    Oseltamivir-resistant novel Influenza A (H1N1) virus infection in two immunosuppressed patients—Seattle, WA, 2009. MMWR Morb Mortal Wkly Rep. 2009;58 (Dispatch, August 14);1–4.Google Scholar
  6. 6.
    Shinde V, Bridges CB, Uyeki TM, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005–2009. N Engl J Med. 2009;360:2616–25.CrossRefPubMedGoogle Scholar
  7. 7.
    World Health Organization. Influenza-like illness in the United States and Mexico, 24 April 2009. (Available at http://www.who.int/csr/don/2009_04_24/en/index.html).
  8. 8.
    Cohen J. Swine flu outbreak. Out of Mexico? Scientists ponder swine flu’s origins. Science. 2009;324:700.CrossRefPubMedGoogle Scholar
  9. 9.
    Machado CM, Boas LS, Mendes AV, et al. Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant. 2003;31:695–700.CrossRefPubMedGoogle Scholar
  10. 10.
    Chemaly RF, Torres HA, Aguilera EA, et al. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis. 2007;44:964–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Engelhard D, Nagler A, Hardan I, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant. 1993;11:1–5.PubMedGoogle Scholar
  12. 12.
    Cordonnier C, Labopin M, Chesnel V, et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis. 2009;48:1392–401.CrossRefPubMedGoogle Scholar
  13. 13.
    Machado CM, Cardoso MRA, da Rocha IF, Boas LSV, Dulley FL, Pannuti CS. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant. 2005;36:897–900.CrossRefPubMedGoogle Scholar
  14. 14.
    Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med. 2003;348:867–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Medeiros R, Rameix-Welti MA, Lorin V, et al. Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus. Antivir Ther. 2007;12:571–6.PubMedGoogle Scholar
  16. 16.
    Khanna N, Steffen I, Studt JD, et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2009;11(2):100–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Kobayashi S, Kimura F, Kobayashi A, Sato K, Motoyoshi K. Influenza virus reactivation after remission with oseltamivir treatment in a patient undergoing nonmyeloablative bone marrow transplantation. J Infect Chemother. 2008;14(4):308–10.CrossRefPubMedGoogle Scholar
  18. 18.
    Wingard JR. Influenza: preparedness for an inevitable “Emergency” for oncology and BMT units. Natl Compr Canc Netw. 2008;6:215–22.Google Scholar

Copyright information

© The Japanese Society of Hematology 2009

Authors and Affiliations

  • Mohamed A. Kharfan-Dabaja
    • 1
    • 2
  • Ana Velez
    • 1
    • 2
    • 3
  • Karla Richards
    • 1
  • John N. Greene
    • 1
    • 2
    • 3
  • Teresa Field
    • 1
    • 2
  • Ramon Sandin
    • 1
    • 2
    • 4
  1. 1.Department of Blood and Marrow TransplantationH. Lee Moffitt Cancer Center and Research InstituteTampaUSA
  2. 2.Department of Oncological SciencesH. Lee Moffitt Cancer Center and Research Institute/University of South FloridaTampaUSA
  3. 3.Division of Infectious DiseasesH. Lee Moffitt Cancer Center and Research Institute/University of South FloridaTampaUSA
  4. 4.Department of Hematopathology and Laboratory MedicineH. Lee Moffitt Cancer Center and Research InstituteTampaUSA

Personalised recommendations